Tenomix

tenomix.com
Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
The first-ever automated, bench-top robotic scanning device for the detection of lymph nodes in surgically removed colorectal cancer tissue, making this step less labour intensive, less costly, and more reliable resulting in better patient care.

Related news

FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic

FACIT congratulates London, Ontario based Tenomix Inc. (“Tenomix”) on successfully reaching a key milestone in closing its latest financing round to help propel the medtech start-up. Tenomix’s bench-top device will save time and costs by automating the process of lymph node identification in resected tissue while providing more accurate cancer staging for better patient care. Read More

Women-led health and biotech companies dominate FACIT's latest investments

On the globally-recognized Women’s Entrepreneurship Day, FACIT is pleased to announce investments in four breakthrough oncology innovations – all driven by women leaders. November 19th each year is a day to celebrate and showcase women’s contributions to advance communities and to strengthen their empowerment in the entrepreneurial ecosystem to drive economic impact. FACIT’s support of the four ventures, Virano Therapeutics, Hyivy Health, Tenomix Inc., and DTPx Therapeutics are representative of an asset portfolio where over one third are women-led or founded innovations, attracting one third of every dollar invested by FACIT – as much as ten times the average for the venture capital industry. Read More

FACIT and OBIO® partner on women-focused seed capital and entrepreneurship program

On International Women’s Day, FACIT and OBIO® are pleased to announce a new partnership in the Ontario life sciences ecosystem, built on their common goal to drive entrepreneurial and commercialization mandates to address the unmet needs and barriers faced by female entrepreneurial leaders in STEM. Read More

FACIT generates $1.5 billion in follow-on investment

FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.